Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SRRK, Rayzebio, CRGX, MLYS, ACLX, and represent 62.57% of Samsara BioCapital's stock portfolio.
- Added to shares of these 9 stocks: CRGX (+$95M), SRRK (+$41M), NGNE (+$25M), ABVX (+$9.1M), SYRS (+$7.0M), SLRN, VTVT, LPTX, Science 37 Holdings.
- Started 5 new stock positions in ABVX, VTVT, CRGX, Science 37 Holdings, NGNE.
- Reduced shares in these 8 stocks: , ACLX (-$8.5M), RYTM (-$7.9M), IMCR, EYPT, PEPG, Vtv Therapeutics Inc- Cl A, Science 37 Holdings.
- Sold out of its positions in EYPT, IMCR, Intercept Pharmaceuticals In, Science 37 Holdings, Vtv Therapeutics Inc- Cl A.
- Samsara BioCapital was a net buyer of stock by $141M.
- Samsara BioCapital has $643M in assets under management (AUM), dropping by 96.76%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 41 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Scholar Rock Hldg Corp (SRRK) | 19.9 | $128M | +47% | 6.8M | 18.80 |
|
| Rayzebio | 17.9 | $115M | 1.8M | 62.17 |
|
|
| Cargo Therapeutics (CRGX) | 14.8 | $95M | NEW | 4.1M | 23.15 |
|
| Mineralys Therapeutics (MLYS) | 6.0 | $39M | 4.5M | 8.60 |
|
|
| Arcellx Common Stock (ACLX) | 4.0 | $26M | -24% | 460k | 55.50 |
|
| Neurogene (NGNE) | 3.8 | $25M | NEW | 1.3M | 19.38 |
|
| Graphite Bio | 3.4 | $22M | 8.5M | 2.62 |
|
|
| Nkarta (NKTX) | 2.9 | $19M | 2.9M | 6.60 |
|
|
| Acelyrin (SLRN) | 2.9 | $19M | +5% | 2.5M | 7.46 |
|
| Zymeworks Del (ZYME) | 2.4 | $15M | 1.5M | 10.39 |
|
|
| Lyra Therapeutics (LYRA) | 2.3 | $15M | 2.8M | 5.24 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 2.2 | $14M | +102% | 1.8M | 7.79 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 2.1 | $14M | 968k | 14.12 |
|
|
| Hillevax (HLVX) | 2.0 | $13M | 799k | 16.05 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 1.4 | $9.1M | NEW | 850k | 10.70 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $7.9M | -49% | 173k | 45.97 |
|
| Sutro Biopharma (STRO) | 1.1 | $7.2M | 1.7M | 4.29 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.1 | $6.9M | 348k | 19.88 |
|
|
| Io Biotech (IOBT) | 1.1 | $6.8M | 3.6M | 1.88 |
|
|
| Inozyme Pharma (INZY) | 1.0 | $6.7M | 1.6M | 4.26 |
|
|
| Tango Therapeutics (TNGX) | 1.0 | $6.2M | 630k | 9.90 |
|
|
| Gossamer Bio (GOSS) | 0.9 | $5.6M | 6.1M | 0.91 |
|
|
| Immatics SHS (IMTX) | 0.6 | $4.2M | 396k | 10.53 |
|
|
| Prime Medicine (PRME) | 0.6 | $4.2M | 470k | 8.86 |
|
|
| Janux Therapeutics (JANX) | 0.6 | $3.9M | 360k | 10.73 |
|
|
| Pepgen (PEPG) | 0.5 | $3.0M | -32% | 437k | 6.80 |
|
| Day One Biopharmaceuticals I (DAWN) | 0.4 | $2.9M | 196k | 14.60 |
|
|
| Leap Therapeutics Com New (LPTX) | 0.4 | $2.8M | +11% | 669k | 4.14 |
|
| Rain Therapeutics | 0.4 | $2.4M | 2.0M | 1.20 |
|
|
| Terns Pharmaceuticals (TERN) | 0.2 | $1.3M | 202k | 6.49 |
|
|
| Igm Biosciences (IGMS) | 0.2 | $1.3M | 155k | 8.31 |
|
|
| Bolt Biotherapeutics (BOLT) | 0.2 | $1.2M | 1.0M | 1.12 |
|
|
| Aclaris Therapeutics (ACRS) | 0.1 | $731k | 696k | 1.05 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 0.1 | $470k | NEW | 41k | 11.50 |
|
| Allakos (ALLK) | 0.1 | $470k | 172k | 2.73 |
|
|
| Viracta Therapeutics (VIRX) | 0.1 | $393k | 690k | 0.57 |
|
|
| Science 37 Holdings Com New | 0.0 | $240k | NEW | 45k | 5.34 |
|
| Kronos Bio (KRON) | 0.0 | $98k | 78k | 1.25 |
|
|
| Allovir (ALVR) | 0.0 | $56k | 82k | 0.68 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $8.0k | 133k | 0.06 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.9k | 100k | 0.02 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023
- Samsara BioCapital 2022 Q3 filed Nov. 14, 2022
- Samsara BioCapital 2022 Q2 filed Aug. 15, 2022
- Samsara BioCapital 2022 Q1 filed May 16, 2022
- Samsara BioCapital 2021 Q4 filed Feb. 14, 2022
- Samsara BioCapital 2021 Q3 filed Nov. 15, 2021
- Samsara BioCapital 2021 Q2 filed Aug. 17, 2021
- Samsara BioCapital 2021 Q1 filed May 18, 2021
- Samsara BioCapital 2020 Q4 filed Feb. 17, 2021
- Samsara BioCapital 2020 Q3 filed Nov. 16, 2020